This result indicates that the antiepileptic effects of ADAM10 that act via amyloidogenic processes most likely depend on APP overexpression.4 Hence, the incremental modulation of ADAM10 in amyloidogenic processes seems to be limited to treating epileptic seizures in AD. The gene discussed is ADAM10; the disease is Alzheimer disease.